FDA Rejects Corcept's Relacorilant Application; Securities Lawsuits Follow
Corcept Therapeutics received an FDA Complete Response Letter denying approval of relacorilant for hypertension secondary to hypercortisolism, triggering a 44.76% stock decline and multiple securities class actions.